Long acting GLP-1 receptor agonist (injectable)
Albiglutide 15 mg injection once weekly
ALBI_SC_15MG_QW
Related
- All doses pooled: Albiglutide injection
- Albiglutide 100 mg injection every 4 weeks
- Albiglutide 4 mg injection once weekly
- Albiglutide 30 mg subcutaneous once weekly
- Albiglutide 15 mg injection every 2 weeks
- Albiglutide 30 mg injection every 2 weeks
- Albiglutide 50 mg injection every 2 weeks
- Albiglutide 50 mg injection every 4 weeks
- Albiglutide flexible dose injection once weekly
- Albiglutide 50 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.06 (0.24 to 3.44) | 0.47 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.36 (0.52 to 3.24) | 0.70 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.54 (0.35 to 5.35) | 0.65 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.41 (0.08 to 1.49) | 0.89 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.47 (0.35 to 12.44) | 0.37 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.93 (0.05 to 16.81) | 0.46 |